581076-63-3

Basic information

• Product Name: N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE
• Synonyms: N-(3-aMino-4-Methylphenyl) -4-((4-Methylpiperazin-1-yl) Methyl)benzaMide;N-(3-amino-4-methylphenyl)-4-[(4-methyl-1-piperazinyl)methyl]benzamide;N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE;N-(3-Amino-4-methyl-phenyl)-4-(4-methyl-piperazin-1-yl)-benzamide
• CAS NO: 581076-63-3
• Molecular Formula: C20H26N4O
• Molecular Weight: 338.44664
• Product Categories: Aromatics Compounds;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 581076-63-3.mol

Chemical Properties

• Boiling Point: 454.2±45.0 °C(Predicted)
• Appearance: /
• Density: 1.190±0.06 g/cm3(Predicted)
• Solubility: Chloroform
• PKA: 13.35±0.70(Predicted)
• CAS DataBase Reference: N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE(581076-63-3)
• EPA Substance Registry System: N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE(581076-63-3)

Safety Data

• Hazardous Substances Data: 581076-63-3(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE is used as a synthetic building block for the creation of various organic compounds. Its unique structure allows it to be a valuable component in the synthesis of complex molecules, potentially leading to the development of new pharmaceuticals, agrochemicals, or other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE is used as a key intermediate in the development of new drugs. Its specific chemical properties make it a promising candidate for the synthesis of novel therapeutic agents, potentially targeting a wide range of medical conditions.
Used in Research and Development:
N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE is also utilized in research and development settings, where it can be employed to study the properties and reactivity of similar compounds. This can lead to a better understanding of their potential applications and the discovery of new chemical reactions or processes.
Used in Chemical Analysis:
Due to its distinctive chemical properties, N-(4-METHYL-3-AMINOPHENYL)-4-(4-METHYLPIPERAZINOMETHYL)BENZAMIDE can be used in chemical analysis to identify and characterize other compounds. It may serve as a reference material or be involved in the development of new analytical methods, contributing to the advancement of chemical research and technology.

Upstream product

• 1571-08-0 methyl 4-formylbenzoate 
• 95-80-7 4-methylbenzene-1,3-diamine 
• 314268-40-1 4-((4-methylpiperazin-1-yl)methyl)-benzoic acid methyl ester 
• 119-32-4 4-Methyl-3-nitroanilin 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 106261-48-7 4-(4-methylpiperazin-1-ylmethyl)benzoic acid 
• 619-66-9 4-Carboxybenzaldehyde 
• 581076-60-0 N-(4-methyl-3-nitrophenyl)-4-[(4-methylpiprazin-1-yl)methyl]benzamide 
• 109-01-3 1-methyl-piperazine 
• 368879-17-8 4-[(4-methylpiperazin-1-yl)methyl]bromobenzene 
• 201230-82-2 carbon monoxide 

Relevant articles and documents

N-phenyl-2-pyrimidine-amine derivatives

The present invention relates to novel amides and a process for preparing these amides.

Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors

Efforts were made to improve a series of potent dual ABL/SRC inhibitors based on a 7-azaindole core with the aim of developing compounds that demonstrate a wider activity on selected oncogenic kinases. Multi-targeted kinase inhibitors (MTKIs) were then derived, focusing on kinases involved in both angiogenesis and tumorigenesis processes. Antiproliferative activity studies using different cellular models led to the discovery of a lead candidate (6z) that combined both antiangiogenic and antitumoral effects. The activity of 6z was assessed against a panel of kinases and cell lines including solid cancers and leukemia cell models to explore its potential therapeutic applications. With its potency and selectivity for oncogenic kinases, 6z was revealed to be a focused MTKI that should have a bright future in fighting a wide range of cancers.

AZAINDOLE DERIVATIVES AS MULTI KINASE INHIBITORS

The present invention relates to compounds of the following formula (I) and/or the pharmaceutically acceptable addition salts, solvates, enantiomers, diastereoisomers thereof, as well as mixtures thereof. The subject matter of the present invention thus also includes the preparation of compounds of formula (I), their uses, in particular in the inhibition of protein kinases which are implicated for example in numerous diseases such as cancers or immune system disorders.

Synthesis of new amides of the N-methylpiperazine series

New carboxylic acid amides containing an N-methylpiperazine fragment were synthesized by reactions of 1-methylpiperazine or 3- and 4-(4-methylpiperazin-1- ylmethyl)aniline with 4-chlorobenzoyl chloride and of 4-methyl-3-nitroaniline with 4-(4-methylpiperazin-1-ylmethyl)benzoyl chloride or benzotriazol-1-yl 4-(4-methylpiperazin-1-ylmethyl)benzoate. 4-Chloro-N-[4-(4-methylpiperazin-1- ylmethyl)phenyl]benzamide reacted with imidazole, quinolin-5-amine, and 2-methylquinolin-5-amine to give substituted 4-amino-N-[4-(4- methylpiperazin-1-ylmethyl)phenyl]benzamides. 4-Methyl-3-nitrophenyl-4- methylpiperazin-1-yl-substituted benzamides were reduced with hydrazine hydrate over Raney nickel to obtain N-(3-amino-4-methylphenyl)-4- (4-methylpiperazin-1- ylmethyl)benzamide as key intermediate in the synthesis of antileukemic agent imatinib and its isomer with alternative position of the amide group, 4-[(3-amino-4-methylphenylamino)methyl]phenyl- (4-methylpiperazin-1-yl)} methanone. Pleiades Publishing, Ltd., 2011.

GLEEVEC PROCESS

The invention provides a process for the production of a pharmaceutical intermediate compound in accordance with the following scheme (formula (I)), wherein R5 is any suitable substituent group; and Z is any suitable leaving group.

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, Bmx, CSK, TrkB, FGFR3, Fes, Lck, B-RAF, C-RAF, MKK6, SAPK2alpha and SAPK2beta kinases.